藤黄健骨胶囊治疗骨质疏松的循证药物经济学评价

Pharmacoeconomic Evaluation of Evidence-based Drugs for Treatment of Osteoporosis with Tenghuangjiangu Capsule

目的基于Meta分析对藤黄健骨胶囊治疗骨质疏松的经济性进行评价。方法根据文献纳入和排除标准系统性检索各中英文数据库,对藤黄健骨胶囊联合常规疗法对比单用常规疗法治疗骨质疏松的随机对照临床研究进行汇总分析。采用RevMan 5.4软件对纳入文献数据进行处理,得到临床有效率,采用文献中数据骨折发生率构建决策树模型进行成本-效果分析,研究角度为卫生体系角度,并进行敏感性分析验证结果的稳健性。成本数据来源于药智网和文献。结果经Meta分析可得,藤黄健骨胶囊联合常规疗法与常规疗法的临床有效率分别为93.34%和76.72%,两组成本分别为2683.63元和2970.03元,增量成本-效果比(ICER)<0,敏感性分析验证结果稳健性良好。结论与常规疗法相比,藤黄健骨胶囊联合常规疗法治疗骨质疏松可提高临床有效率,降低骨折发生率,更节省患者治疗成本。藤黄健骨胶囊治疗骨质疏松为经济优势方案。

Objective Based on meta-analysis to evaluate the economics of Tenghuang Jiangu Capsules in the treatment of osteoporosis.Methods A systematic search of various Chinese and English databases according to the standard of literature inclusion and discharge,and a pooled analysis of randomized controlled clinical studies of Tenghuang Jiangu Capsules combined with conventional therapy versus conventional therapy alone in the treatment of osteoporosis.RevMan 5.4 software was used to process the included literature data to obtain the total clinical effectiveness.The data in the literature was used to construct a decision tree model for cost-effectiveness analysis.The research angle was the health system perspective,and sensitivity analysis was performed to verify the robustness of the results.The cost data comes from Yaozhi.com and literature.Results According to meta-analysis,the total clinical effective rate of Tenghuang Jiangu Capsules with conventional therapies and conventional therapies was 93.34%and 76.72%,respectively.The costs of the 2 groups were 2683.63 yuan and 2970.03 yuan,respectively,(ICER<0),sensitivity analysis and verification results are robust.Conclusion Compared with conventional therapies,Tenghuang Jiangu Capsules can improve the clinical effectiveness of osteoporosis,reduce the incidence of fractures,and save patients'treatment costs.The treatment of osteoporosis with Tenghuang Jiangu Capsules is an economic advantage program.